Edition:
United Kingdom

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

10.66USD
6:23pm BST
Change (% chg)

$-0.14 (-1.30%)
Prev Close
$10.80
Open
$10.80
Day's High
$10.85
Day's Low
$10.63
Volume
6,193
Avg. Vol
64,717
52-wk High
$21.25
52-wk Low
$6.31

Latest Key Developments (Source: Significant Developments)

Syros Announces Proposed Offering Of Common Stock
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SYROS PHARMACEUTICALS INC - ‍OFFERING TO SELL $40.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING​.  Full Article

Syros Announces 2018 Strategic Priorities And Expected Milestones
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES.ON TRACK TO REPORT CLINICAL DATA ON SY-1425 COMBINATIONS AND SY-1365.CO HAD ABOUT $81.9 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPT 30, 2017.EXPECTS TO BE ABLE TO FUND ANTICIPATED OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019.  Full Article

Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Incyte Corp ::INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT.INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​.INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​.INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS.INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​.INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES.INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES.INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS.SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS' ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425.SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT.SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​.  Full Article

Syros Pharma Q3 loss per share $0.53
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Syros Pharmaceuticals Inc :Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones.Q3 loss per share $0.53.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48

* SYROS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES